Co-Administration of Adjuvanted Recombinant Ov -103 and Ov -RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis.

Autor:	Luu L; Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool L3 5RF, UK., Bah GS; L'Institut de Recherche Agricole Pour le Deéveloppement (IRAD), Yaoundé 2123, Cameroon., Okah-Nnane NH; L'Institut de Recherche Agricole Pour le Deéveloppement (IRAD), Yaoundé 2123, Cameroon., Hartley CS; Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool L3 5RF, UK., Glover AF; Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool L3 5RF, UK., Walsh TR; Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool L3 5RF, UK., Lian LY; Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L3 5RF, UK., Zhan B; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA., Bottazzi ME; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA., Abraham D; Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA., Petrovsky N; Flinders Medical Centre, Adelaide 5042, Australia., Bayang N; L'Institut de Recherche Agricole Pour le Deéveloppement (IRAD), Yaoundé 2123, Cameroon., Tangwa B; L'Institut de Recherche Agricole Pour le Deéveloppement (IRAD), Yaoundé 2123, Cameroon., Ayiseh RB; Biotechnology Unit, University of Buea, Buea P.O. Box 63, Cameroon., Mbah GE; Department of Biology, Higher Teacher Training College (HTTC), The University of Bamenda, Bambili P.O. Box 39, Cameroon., Ekale DD; L'Institut de Recherche Agricole Pour le Deéveloppement (IRAD), Yaoundé 2123, Cameroon., Tanya VN; L'Institut de Recherche Agricole Pour le Deéveloppement (IRAD), Yaoundé 2123, Cameroon., Lustigman S; Molecular Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA., Makepeace BL; Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool L3 5RF, UK., Graham-Brown J; Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool L3 5RF, UK.
Jazyk:	angličtina
Zdroj:	Vaccines [Vaccines (Basel)] 2022 May 27; Vol. 10 (6). Date of Electronic Publication: 2022 May 27.
DOI:	10.3390/vaccines10060861
Abstrakt:	Onchocerciasis (river blindness), caused by the filarial nematode Onchocerca volvulus , is a neglected tropical disease mainly of sub-Saharan Africa. Worldwide, an estimated 20.9 million individuals live with infection and a further 205 million are at risk of disease. Current control methods rely on mass drug administration of ivermectin to kill microfilariae and inhibit female worm fecundity. The identification and development of efficacious vaccines as complementary preventive tools to support ongoing elimination efforts are therefore an important objective of onchocerciasis research. We evaluated the protective effects of co-administering leading O. volvulus -derived recombinant vaccine candidates ( Ov -103 and Ov -RAL-2) with subsequent natural exposure to the closely related cattle parasite Onchocerca ochengi . Over a 24-month exposure period, vaccinated calves ( n = 11) were shown to acquire infection and microfilaridermia at a significantly lower rate compared to unvaccinated control animals ( n = 10). Furthermore, adult female worm burdens were negatively correlated with anti- Ov -103 and Ov -RAL-2 IgG1 and IgG2 responses. Peptide arrays identified several Ov -103 and Ov -RAL-2-specific epitopes homologous to those identified as human B-cell and helper T-cell epitope candidates and by naturally-infected human subjects in previous studies. Overall, this study demonstrates co-administration of Ov -103 and Ov -RAL-2 with Montanide™ ISA 206 VG is highly immunogenic in cattle, conferring partial protection against natural challenge with O. ochengi . The strong, antigen-specific IgG1 and IgG2 responses associated with vaccine-induced protection are highly suggestive of a mixed Th1/Th2 associated antibody responses. Collectively, this evidence suggests vaccine formulations for human onchocerciasis should aim to elicit similarly balanced Th1/Th2 immune responses.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu